Mitchell Mcleod Pugh & Williams Inc. Purchases 2,000 Shares of Stryker Corporation $SYK

Mitchell Mcleod Pugh & Williams Inc. increased its stake in Stryker Corporation (NYSE:SYK) by 309.1% in the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 2,647 shares of the medical technology company’s stock after purchasing an additional 2,000 shares during the quarter. Mitchell Mcleod Pugh & Williams Inc.’s holdings in Stryker were worth $948,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in SYK. Norges Bank acquired a new stake in Stryker in the 4th quarter worth approximately $1,822,272,000. Corient Private Wealth LLC lifted its holdings in Stryker by 104.4% in the 2nd quarter. Corient Private Wealth LLC now owns 2,245,841 shares of the medical technology company’s stock worth $887,525,000 after purchasing an additional 1,146,998 shares during the last quarter. Alliancebernstein L.P. lifted its holdings in Stryker by 13.3% in the 3rd quarter. Alliancebernstein L.P. now owns 6,338,050 shares of the medical technology company’s stock worth $2,342,987,000 after purchasing an additional 741,542 shares during the last quarter. Strive Asset Management LLC acquired a new stake in Stryker in the 3rd quarter worth approximately $227,389,000. Finally, Credit Agricole S A acquired a new stake in Stryker in the 3rd quarter worth approximately $194,045,000. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Stryker Stock Down 1.8%

Shares of SYK stock opened at $308.50 on Thursday. Stryker Corporation has a 12 month low of $281.00 and a 12 month high of $404.87. The firm has a market cap of $118.27 billion, a PE ratio of 35.71, a price-to-earnings-growth ratio of 1.98 and a beta of 0.78. The stock has a 50 day moving average of $317.20 and a 200-day moving average of $344.64. The company has a quick ratio of 1.25, a current ratio of 2.11 and a debt-to-equity ratio of 0.62.

Stryker (NYSE:SYK) last issued its quarterly earnings results on Thursday, April 30th. The medical technology company reported $2.60 EPS for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). Stryker had a return on equity of 23.42% and a net margin of 13.20%.The business had revenue of $6.02 billion for the quarter, compared to analyst estimates of $6.34 billion. During the same quarter last year, the firm earned $2.84 earnings per share. The firm’s quarterly revenue was up 2.6% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. On average, equities analysts predict that Stryker Corporation will post 14.98 EPS for the current year.

Stryker Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Tuesday, June 30th will be issued a dividend of $0.88 per share. The ex-dividend date is Tuesday, June 30th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.1%. Stryker’s payout ratio is 40.74%.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on SYK shares. Canaccord Genuity Group reduced their target price on Stryker from $435.00 to $400.00 and set a “buy” rating for the company in a report on Friday, May 1st. Barclays reduced their target price on Stryker from $469.00 to $394.00 and set an “overweight” rating for the company in a report on Monday, May 4th. Jefferies Financial Group restated a “buy” rating and issued a $465.00 target price on shares of Stryker in a report on Wednesday, March 4th. Truist Financial restated a “hold” rating and issued a $330.00 target price (down from $380.00) on shares of Stryker in a report on Monday, May 4th. Finally, Sanford C. Bernstein set a $410.00 price target on Stryker in a report on Friday, May 1st. Sixteen investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $395.33.

Insider Transactions at Stryker

In related news, VP Robert S. Fletcher sold 4,544 shares of the company’s stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $306.87, for a total value of $1,394,417.28. Following the completion of the transaction, the vice president directly owned 10,582 shares in the company, valued at approximately $3,247,298.34. This represents a 30.04% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Ronda E. Stryker sold 310,000 shares of the company’s stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total value of $96,791,300.00. Following the completion of the transaction, the director owned 1,924,880 shares of the company’s stock, valued at $601,005,282.40. The trade was a 13.87% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 323,264 shares of company stock worth $100,659,489 over the last three months. 4.60% of the stock is currently owned by insiders.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.